Statins and fibrates do not affect development of spontaneous cartilage damage in STR/Ort mice

Osteoarthritis and Cartilage

Volumn 22, Issue 2, 2014, Pages 293-301

  Wei, W ^a   Clockaerts, S ^a,b   Bastiaansen Jenniskens, Y M ^a   Gierman, L M ^c,d   Botter, S M ^e   Bierma Zeinstra, S M A ^a   Weinans, H ^a,f,g   Verhaar, J A N ^a   Kloppenburg, M ^d   Zuurmond, A M ^c   Van Osch, G J V M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c TNO   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^f DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cartilage; Mouse; Osteoarthritis; Subchondral bone; Therapy pharmacological

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P70; SERUM AMYLOID A; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE INJURY; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; INFLAMMATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; SUBCHONDRAL BONE PLATE; SYNOVIUM; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

CARTILAGE; MOUSE; OSTEOARTHRITIS; SUBCHONDRAL BONE; THERAPY PHARMACOLOGICAL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; BODY WEIGHT; CARTILAGE, ARTICULAR; DIET; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FENOFIBRATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED STRAINS; OSTEOARTHRITIS; SIMVASTATIN; X-RAY MICROTOMOGRAPHY;

EID: 84893725682     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.11.009     Document Type: Article

References (50)

1. Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011, 377:2115-2126.
2. Aspden R.M., Scheven B.A., Hutchison J.D. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet 2001, 357:1118-1120.
3. Oliveria S.A., Felson D.T., Reed J.I., Cirillo P.A., Walker A.M. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995, 38:1134-1141.
4. Zhuo Q., Yang W., Chen J., Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 2012, 8:729-737.
5. Hoeven T.A., Kavousi M., Clockaerts S., Kerkhof H.J.M., van Meurs J.B., Franco O., et al. Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study. Annals of the Rheumatic Diseases 2012, 72:646-651.
6. Devaraj S., Chan E., Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. JClin Endocrinol Metab 2006, 91:4489-4496.
7. Abe M., Matsuda M., Kobayashi H., Miyata Y., Nakayama Y., Komuro R., et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008, 28:871-877.
8. Baker J., Walsh P., Byrne D., Mulhall K. Pravastatin suppresses matrix metalloproteinase expression and activity in human articular chondrocytes stimulated by interleukin-1β. JOrthop Traumatol 2012, 13:110-123.
9. Clockaerts S., Bastiaansen-Jenniskens Y.M., Feijt C., Verhaar J.A., Somville J., De Clerck L.S., et al. Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage. Osteoarthritis Cartilage 2011, 19:895-902.
10. Clockaerts S., Bierma-Zeinstra S.M. Comment on: statins and the joint: multiple target for a global protection?. Semin Arthritis Rheum 2011, 40:588.
11. Dombrecht E.J., Van Offel J.F., Bridts C.H., Ebo D.G., Seynhaeve V., Schuerwegh A.J., et al. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin Exp Rheumatol 2007, 25:534-539.
12. Lazzerini P.E., Capecchi P.L., Nerucci F., Fioravanti A., Chellini F., Piccini M., et al. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 2004, 63:867-869.
13. Lazzerini P.E., Lorenzini S., Selvi E., Capecchi P.L., Chindamo D., Bisogno S., et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 2007, 25:696-700.
14. Yudoh K., Karasawa R. Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging (Albany NY) 2010, 2:990-998.
15. Clockaerts S., Van Osch G.J., Bastiaansen-Jenniskens Y.M., Verhaar J.A., Van Glabbeek F., Van Meurs J.B., et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012, 71:642-647.
16. Kadam U.T., Blagojevic M., Belcher J. Statin use and clinical osteoarthritis in the general population: a longitudinal study. JGen Intern Med 2013, 28:943-949.
17. van Eekeren I.C., Clockaerts S., Bastiaansen-Jenniskens Y.M., Lubberts E., Verhaar J.A., van Osch G.J., et al. Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review. Ther Adv Musculoskelet Dis 2013, 5:33-44.
18. Mason R.M., Chambers M.G., Flannelly J., Gaffen J.D., Dudhia J., Bayliss M.T. The STR/ort mouse and its use as a model of osteoarthritis. Osteoarthritis Cartilage 2001, 9:85-91.
19. Uchida K., Urabe K., Naruse K., Ogawa Z., Mabuchi K., Itoman M. Hyperlipidemia and hyperinsulinemia in the spontaneous osteoarthritis mouse model, STR/Ort. Exp Anim 2009, 58:181-187.
20. Watters J.W., Cheng C., Pickarski M., Wesolowski G.A., Zhuo Y., Hayami T., et al. Inverse relationship between matrix remodeling and lipid metabolism during osteoarthritis progression in the STR/Ort mouse. Arthritis Rheum 2007, 56:2999-3009.
21. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
22. Waarsing J.H., Day J.S., Weinans H. An improved segmentation method for invivo microCT imaging. JBone Miner Res 2004, 19:1640-1650.
23. Botter S.M., van Osch G.J., Clockaerts S., Waarsing J.H., Weinans H., van Leeuwen J.P. Osteoarthritis induction leads to early and temporal subchondral plate porosity in the tibial plateau of mice: an invivo microfocal computed tomography study. Arthritis Rheum 2011, 63:2690-2699.
24. Glasson S.S., Chambers M.G., Van Den Berg W.B., Little C.B. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010, 18(Suppl 3):S17-S23.
25. Naruse K., Urabe K., Jiang S.X., Uchida K., Kozai Y., Minehara H., et al. Osteoarthritic changes of the patellofemoral joint in STR/OrtCrlj mice are the earliest detectable changes and may be caused by internal tibial torsion. Connect Tissue Res 2009, 50:243-255.
26. Kleemann R., Princen H.M., Emeis J.J., Jukema J.W., Fontijn R.D., Horrevoets A.J., et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003, 108:1368-1374.
27. Sparrow C.P., Burton C.A., Hernandez M., Mundt S., Hassing H., Patel S., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001, 21:115-121.
28. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979, 575:266-276.
29. Weng T.C., Yang Y.H., Lin S.J., Tai S.H. Asystematic review and meta-analysis on the therapeutic equivalence of statins. JClin Pharm Ther 2010, 35:139-151.
30. Paraskevas K.I., Pantopoulou A., Vlachos I.S., Agrogiannis G., Iliopoulos D.G., Karatzas G., et al. Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology 2011, 62:144-154.
31. Fraulob J.C., Souza-Mello V., Aguila M.B., Mandarim-de-Lacerda C.A. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012, 123:259-270.
32. Gierman L.M., van der Ham F., Koudijs A., Wielinga P.Y., Kleemann R., Kooistra T., et al. Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice. Arthritis Rheum 2012, 64:1172-1181.
33. Sokoloff L., Mickelsen O., Silverstein E., Jay G.E., Yamamoto R.S. Experimental obesity and osteoarthritis. Am J Physiol 1960, 198:765-770.
34. Okamoto H., Katagiri Y., Kiire A., Momohara S., Kamatani N. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. JRheumatol 2008, 35:752-756.
35. McNiff P.A., Stewart C., Sullivan J., Showell H.J., Gabel C.A. Synovial fluid from rheumatoid arthritis patients contains sufficient levels of IL-1 beta and IL-6 to promote production of serum amyloid A by Hep3B cells. Cytokine 1995, 7:209-219.
36. King V.L., Thompson J., Tannock L.R. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011, 22:302-307.
37. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
38. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., et al. Global suppression of IL-6-induced acute phase response gene expression after chronic invivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. JBiol Chem 2004, 279:16154-16160.
39. Horiuchi Y., Hirayama S., Soda S., Seino U., Kon M., Ueno T., et al. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. JAtheroscler Thromb 2010, 17:722-729.
40. Hu Y., Tong G., Xu W., Pan J., Ryan K., Yang R., et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res 2009, 6:262-268.
41. Ramadori G., Van Damme J., Rieder H., Meyer zum Buschenfelde K.H. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988, 18:1259-1264.
42. Kyostio-Moore S., Nambiar B., Hutto E., Ewing P.J., Piraino S., Berthelette P., et al. STR/ort mice, a model for spontaneous osteoarthritis, exhibit elevated levels of both local and systemic inflammatory markers. Comp Med 2011, 61:346-355.
43. Mahjoub M., Berenbaum F., Houard X. Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int 2012, 23(Suppl 8):841-846.
44. Botter S.M., Glasson S.S., Hopkins B., Clockaerts S., Weinans H., van Leeuwen J.P., et al. ADAMTS5-/- mice have less subchondral bone changes after induction of osteoarthritis through surgical instability: implications for a link between cartilage and subchondral bone changes. Osteoarthritis Cartilage 2009, 17:636-645.
45. Drugs.com Fenofibrate Official FDA Information, Side Effects and Uses 2013, Drugs.com.
46. Drugs.com Simvastatin Orally Disintegrating Tablet Official FDA Information, Side Effects and Uses 2013, Drugs.com.
47. Tenenbaum A., Medvedofsky D., Fisman E.Z., Bubyr L., Matetzky S., Tanne D., et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One 2012, 7:e35298.
48. Derosa G., Maffioli P., Salvadeo S.A., Ferrari I., Gravina A., Mereu R., et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009, 25:1973-1983.
49. Wagner A.M., Sanchez-Quesada J.L., Benitez S., Bancells C., Ordonez-Llanos J., Perez A. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Res Clin Pract 2011, 93:e25-e28.
50. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009, 11:89-94.